Epidermolysis Bullosa Pruriginosa Treated With Upadacitinib

JAMA Dermatol. 2024 Oct 1;160(10):1124-1125. doi: 10.1001/jamadermatol.2024.2787.
No abstract available

Plain language summary

This case series measured the results of using upadacitinib for moderate or severe cases of epidermolysis bullosa pruriginosa.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Adult
  • Epidermolysis Bullosa Dystrophica / drug therapy
  • Epidermolysis Bullosa Dystrophica / pathology
  • Female
  • Heterocyclic Compounds, 3-Ring* / administration & dosage
  • Heterocyclic Compounds, 3-Ring* / adverse effects
  • Heterocyclic Compounds, 3-Ring* / therapeutic use
  • Humans
  • Male
  • Treatment Outcome
  • Young Adult

Substances

  • Heterocyclic Compounds, 3-Ring
  • upadacitinib

Supplementary concepts

  • Epidermolysis Bullosa Pruriginosa